Letter to Editor
Authors
Thalassemia Research Center, Mazandaran University of Medical Sciences, Sari, Iran
1. Borgna‑PignattiC, CappelliniMD, De StefanoP, Del VecchioGC,
Forni GL, Gamberini MR, et al. Cardiac morbidity and
mortality in deferoxamine‑or deferiprone‑treated patients with thalassemia major. Blood 2006;107:3733‑7.
2. Moayedi Esfahani BA, Reisi N, Mirmoghtadaei M. Evaluating
the safety and efficacy of silymarin in ß‑thalassemia patients:
A review. Hemoglobin 2015;39:75‑80.
3. Raškovic A, Stilinovic N, Kolarovic J, Vasovic V, Vukmirovic S,
Mikov M. The protective effects of silymarin against
doxorubicin‑induced cardiotoxicity and hepatotoxicity in rats.
Molecules 2011;16:8601‑13.
4. Aniss HA, Said AE, El-Sayed IH, Adly C. Doxorubicin-induced
cardiotoxicity in mice; protection by silymarin. Egypt J Hosp
Med 2012;48:383-93.
5. ZholobenkoA, Modriansky M. Silymarin and its constituents
in cardiac preconditioning. Fitoterapia 2014;97:122‑32.
Forni GL, Gamberini MR, et al. Cardiac morbidity and
mortality in deferoxamine‑or deferiprone‑treated patients with thalassemia major. Blood 2006;107:3733‑7.
2. Moayedi Esfahani BA, Reisi N, Mirmoghtadaei M. Evaluating
the safety and efficacy of silymarin in ß‑thalassemia patients:
A review. Hemoglobin 2015;39:75‑80.
3. Raškovic A, Stilinovic N, Kolarovic J, Vasovic V, Vukmirovic S,
Mikov M. The protective effects of silymarin against
doxorubicin‑induced cardiotoxicity and hepatotoxicity in rats.
Molecules 2011;16:8601‑13.
4. Aniss HA, Said AE, El-Sayed IH, Adly C. Doxorubicin-induced
cardiotoxicity in mice; protection by silymarin. Egypt J Hosp
Med 2012;48:383-93.
5. ZholobenkoA, Modriansky M. Silymarin and its constituents
in cardiac preconditioning. Fitoterapia 2014;97:122‑32.
)